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Summary A 54 years old man underwent directional coronary atherectomy in seg-
ment 7 with a partial deep-cut injury. A sirolimus-eluting stent (SES) was implanted
at the restenosed post-atherectomy lesion. Six months after SES implantation,
intravascular ultrasound (IVUS) examination revealed slight vessel enlargement
although there were no malapposed struts. Optical coherence tomography (OCT)
revealed partial stent malapposition. Ticlopidine was discontinued 3 months
after SES implantation, but aspirin was continued. Twenty-nine months after SES
implantation, after discontinuing aspirin for 7 days for colon polypectomy, the
patient suffered an acute myocardial infarction at the SES implantation site. IVUS
revealed further positive vessel remodeling and slight stent malapposition and OCT
revealed extension of the previous stent malapposition and ulcer-like appearance
around the stent struts. This case demonstrates that even a small partial SES
malapposition that can be detected only by OCT has the potential to enlarge over
time and the late malapposition may result in late thrombosis when anti-platelet
therapy is discontinued.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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ntroduction
irolimus-eluting stent (SES) is now commonly
sed for percutaneous coronary intervention (PCI)
ecause they dramatically reduce the rates of
estenosis, even in small vessels and long lesions
1]. Their long-term efﬁcacy and safety, however,
ave not been satisfactory [2]. A major con-
ern of SES implantation is late stent thrombosis.
ate thrombosis is a very rare, but fatal com-
lication of SES because it may result in acute
yocardial infarction or sudden cardiac death
3]. Here, we report very late stent thrombo-
is 29 months after SES implantation due to late
alapposition. Serial changes of the SES structure
ere observed using optical coherence tomogra-
hy (OCT), which provides high-resolution images
f intra-stent structures [4,5].ase report
irectional atherectomy was performed in the mid-
eft anterior descending artery in a 54 years old
t
w
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(
igure 1 (a) Coronary angiogram (CAG) showed 90% focal,
except for the deep-cut area). (b) Post-percutaneous corona
tent (SES) (Cypher®) was implanted and good dilatation was o
o restenosis at the SES implanted site. (d) Emergency CAG re
ite. (e) The follow-up CAG revealed no change of SES condit291
an with 90% stenosis in March 2004. At that time,
CI was performed without the use of any stents
ecause the coronary angiogram (CAG) revealed
ood dilatation and intravascular ultrasound (IVUS)
xamination showed a partial laceration of the
ntima-media complex due to the deep atherec-
omy. Six months later, in September 2004, we
erformed a follow-up CAG, which showed 90%
ocal, tandem restenosis at the previous debulking
esion site (except for the deep-cut area) (Fig. 1a).
e implanted a 3.5mm× 28mm SES (Cypher®;
ordis, Johnson and Johnson Company) to cover the
otal area of the restenosed lesion. The post-PCI
ngiogram revealed good dilatation (Fig. 1b) and
VUS revealed good stent apposition. Both aspirin
100mg/day) and ticlodipine (200mg/day) were
rescribed. Three months after SES implantation,
he ticlodipine was discontinued, but aspirin ther-
py was continued.
In March 2005, 6 months after the SES implanta-ion, a follow-up CAG was done. In stent restenosis
as not observed by CAG (Fig. 1c). IVUS (Atlantis
R Pro2®, Boston Scientiﬁc Corporation) and OCT
ImageWire®, LightLab imaging) were indicated
tandem restenosis at the previous debulking lesion site
ry intervention CAG. A 3.5mm× 28mm sirolimus-eluting
bserved. (c) Six-month follow-up CAG. The CAG revealed
vealed total occlusion in the middle of the SES implanted
ion.
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Figure 2 (a) The IVUS (Atlantis SR Pro2®) examination for 6 months after SES implantation. IVUS revealed almost
no change in the stent CSA and slight enlargement of the vessel CSA (from 22.1 to 22.7mm2) compared with those
immediately after SES implantation. Each IVUS image revealed good apposition. Number 3 indicates the previous deep-
cut injury site. (b) The IVUS (Eagle Eye®) visualized the small stent malapposition and showed an increased vessel CSA
SA co
I(from 22.7 to 31.1mm2) without a change in the stent C
arrow indicates the SES malapposition.
for better visualization of the SES. IVUS revealed
almost no change in the stent cross-sectional area
(CSA) and slight enlargement of the vessel CSA
(from 22.1 to 22.7mm2) compared with those
immediately after SES implantation. Further, on
a
m
b
ompared with that at the 6-month follow-up. The white
VUS examination all struts seemed to be well
pposed (Fig. 2a). OCT visualized partial small stent
alapposition at the previous deep-cut injury site,
ut thin neointimal tissue was present on almost all
f the struts (Fig. 3a).
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Figure 3 (a) Optical coherence tomography (OCT) images of 6 months after SES implantation. OCT visualized thin
neointimal tissue on almost all of the well-apposed stent struts, but revealed some partial stent malapposition at
the previous deep-cut injury site (indicated by white arrows). (b) OCT images of 29 months after SES implantation
(post-late thrombosis). OCT revealed more extensive malapposition than that observed at the 6-month follow-up and it
w m th
b like
a
t
b
d
s
ias expanding over the previous deep-cut injury site (fro
are metal stent). Numbers 3, 4, 5 indicate the ulcer-
rrows).
In February 2007, 29 months after SES implanta-
ion, aspirin therapy was temporarily discontinued
ecause of a planned colon polypectomy. Seven
ays after discontinuing the aspirin, the patient
uddenly experienced severe chest pain after tak-
A
e
w
m
Table 1 Changes in stent and vessel cross-sectional area
ultrasound examination
Immediately after SES implantation (mm
Stent CSA 9.7
Vessel CSA 22.1
SES, sirolimus-eluting stent; CSA, cross-sectional area.e mid to distal edge of the SES, which were overlapping
appearance around the SES struts (indicated by white
ng a bath and presented at our hospital emergently.
n electrocardiogram demonstrated ST-segment
levation on the V2—V6 leads. The patient under-
ent an emergent CAG on suspicion of acute
yocardial infarction. The CAG revealed total
during the course of late thrombosis on intravascular
2) 6 months (mm2) 29 months (mm2)
9.8 10.0
22.7 31.1
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occlusion at the mid SES (Fig. 1d) and emergent
PCI was performed. After guide-wire passage, a
thrombectomy was performed using an aspiration
catheter (Rebirth®; Goodman Co., Ltd.) and a red
thrombus was aspirated. A 3.0mm× 14mm bare
metal stent (BMS) (Duraﬂex®, Avantec Vascular
Corp.) was implanted directly, overlapping the dis-
tal part of the residual SES. At this time, IVUS was
not performed because of the emergent nature of
the case.
After 3 weeks, just before discharge, we per-
formed a follow-up CAG, IVUS (Eagle Eye®, Volcano
Therapeutics Inc.), and OCT. CAG revealed no
change of SES condition (Fig. 1e). IVUS revealed
an increased vessel CSA (from 22.7 to 31.1mm2)
without a change in the SES CSA and visualized
slight stent malapposition mainly at the previous
deep-cut site (Fig. 2b, Table 1). OCT more clearly
revealed an expansion of the previous stent malap-
position and the ulcer-like appearance around the
stent struts from the mid SES to the distal edge,
which overlapped the BMS (Fig. 3b).
Discussion
SESs are now widely used in PCI because they sig-
niﬁcantly reduce the rates of restenosis and target
lesion revascularization compared with BMS [1].
Despite reduced revascularization, SES does not
ensure long-term safety due to the persistent risk
of stent thrombosis [2].
In the present case, we implanted the SES at
a previous deep-cut injury site. After 6 months,
although IVUS showed slight vessel enlargement, no
stent malapposition was observed. OCT, however,
revealed partial stent malapposition at that site.
After thrombosis, although we did not perform pre-
balloon angioplasty before implanting BMS, IVUS
revealed further enlargement of vessel and slight
stent malapposition at there, and OCT also revealed
a progression of the stent malapposition and ulcer-
like appearance around the struts expanding over
the previous deep-cut injury site.
The mechanism of late stent thrombosis of
the SES may be multi-factorial. A recent case
report suggested that the mechanism of SES late
thrombosis is late malapposition and cessation of
a short course of double anti-platelet therapy
[6,7]. In the present case, the combination of
the temporary discontinuation of aspirin therapy
and the progression of late stent malapposition
might have contributed to the development of late
thrombosis.
Late stent malapposition also may be due to
many different factors. We previously reported that
l
o
s
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.2% of SES struts were malapposed at a 6-month
ollow-up by OCT and the predictors of SES malap-
osition were choronic total occlusion (CTO) and
verlapped stenting [4]. We postulate that the
echanism for the increased malapposition in a
TO lesion may be positive vessel remodeling or
he absorption of thrombi with suppressed neointi-
al hyperplasia. As for overlapping SES segments,
xcessive inhibition of neointimal hyperplasia due
o the doubled dose of sirolimus may be a factor.
n the present case, a single SES was implanted
nd there was no CTO lesion, but a partial stent
alapposition was detected around the previous
eep-cut injury site at ﬁrst, and enlarged over time.
akamura et al. reported late malapposition of
MS was associated with vessel enlargement due
o mechanical injury from directional atherectomy
y serial IVUS study. They speculated that vessel
all injury due to aggressive plaque removal might
lter the focal vessel wall compliance and the resul-
ant effects of tensile stress from stretching cause
hronic vessel enlargement [8]. We reported a sim-
lar change when an SES was implanted into an
ntramural hematoma [5]. As shown in Table 1, this
ase also expressed positive vessel remodeling at
-month follow-up study. Therefore, we speculate
hat the mechanism of a ﬁrst stent malapposi-
ion is the combination of arterial wall fragility
nd sirolimus-induced inhibition of intimal hyper-
lasia.
In this case, furthermore, the late malappo-
ition proceeded to the distal edge of the SES
ver the previous deep-cut injury site, leading to
hrombosis. Therefore, the persistent late malap-
osition was not only due to deep-cut injury.
irmani et al. reported that localized hypersensi-
ivity vasculitis in response to an SES implanted
n a human coronary artery led to late stent
alapposition and thrombosis in a pathology study
9]. They observed signiﬁcant malapposition in
oth proximal and distal stents and this pecu-
iar vascular response between the polymer and
he vessel may cause positive remodeling and
e involved in late malapposition and throm-
ogenicity between 8 and 18 months. Although
e did not examine the possibility of an aller-
ic reaction and malapposition was not observed
t the proximal edge, we speculate that local-
zed hypersensitivity vasculitis might also have
een involved in late malapposition and thrombo-
is.ikely to result in late thrombosis, but we have an
pinion that patients with late stent malapposition
hould be encouraged to continue at least one long-
erm anti-platelet therapy.
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